We came across a bullish thesis on Ultragenyx Pharmaceutical Inc. on HalfBakedInnovations’s Substack by Biotech Distilled. In ...

AbbVie recently reported record 2025 results and outlined a stronger 2026 outlook, while advancing key immunology assets and ...

AbbVie ABBV had an encouraging year in 2025, registering a sales growth of about 8.5% year over year at constant exchange ...

AbbVie expects these two drugs to generate more than $31 billion in sales in 2026 — about $0.5 billion above its long-term ...

We are thrilled to welcome Elaine to Artiva’s board at such an important time for the company,” said Fred Aslan, M.D., president and chief executive officer of Artiva Biotherapeutics. “Elaine brings ...

AbbVie leads today's top analyst picks after beating Q4 estimates, while RTX and IBM also draw attention for strong results and growth drivers.

AbbVie, RTX and IBM headline Zacks??? top analyst picks after strong earnings beats and solid backlog, cloud and AI-driven ...

AbbVie Inc. (NYSE:ABBV) Q4 2025 Earnings Call Transcript February 4, 2026 AbbVie Inc. beats earnings expectations. Reported EPS is $2.71, expectations were $2.65. Operator: Good morning, and thank you ...

CVS Health said on Thursday it would swap out Amgen and Eli Lilly's bone disease treatments for lower-cost alternatives in some of ‍its preferred drug lists, starting April 1. Its pharmacy benefit ...

Crystalys Therapeutics Inc. ('Crystalys' or 'the Company'), a clinical-stage biopharmaceutical company addressing the significant unmet medical needs of people living with gout, today announced that ...

Pharm Exec’s 21st Annual Pipeline Report examines emerging drug development classes, treatment modalities, and expansion ...

CVS Health this morning reported earnings in line with expectations. In 2025, the giant healthcare company saw record earnings of $402.1 billion, up 7.8% compared with the year before. The lull-year ...